The COVID-19 vaccine moved the markets once again - Monday Review, December 14

The COVID-19 vaccine moved the markets once again - Monday Review, December 14

Markets were mostly high on COVID-19 vaccine approval

The US

The prospects of new restrictions to curb the spread of COVID-19 infections caused most of the benchmarks to close in the red. USA30 fell 0.62%, while USA500 dropped 0.49%. TECH100 jumped 0.50%.

Crude oil closed the session at $47.15 a barrel after it gained 1.3%.

Gold fell 0.7% to $1,830.25 per ounce.

Asia and Australia

In part, investors were cheered by Pfizer's COVID-19 vaccine's latest approval by the US Food and Drug Administration.

Japan225 rose 0.59%.

HongKong45 lost 0.04% after some major companies like Alibaba, Tencent-backed China Literature, and Hive Box Technology got fines from its market regulator.

Down under, Australia200 gained 0.51% as the market expects the minutes from the Reserve Bank of Australia's latest policy meeting.

Europe

The Brexit negotiations were extended past the Sunday deadline, which led the markets to trade higher. The UK's Prime Minister Boris Johnson and EC President Ursula von der Leyen continue to negotiate a trade deal.

Germany30 and France40 each closed 0.8% higher. UK100 added 0.1%.

Brent oil closed 1.2% higher at $50.55 per barrel.

EUR/USD traded at 1.2144 after it went up 0.3%.

Sources: investing.com, reuters.com

This information prepared by za.capex.com is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.

This information is prepared for general circulation. It does not regard to the specific investment objectives, financial situation or the particular needs of any recipient.

You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.

This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent. Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of za.capex.com

JME Financial Services (Pty) Ltd trading as ZA.CAPEX.COM acts as intermediary between the investor and Magnasale Trading Ltd, the counterparty to the contract for difference purchased by the Investor via ZA.CAPEX.COM, authorised & regulated by the Cyprus Securities and Exchange Commission with license number 264/15. Magnasale Trading Ltd is the principal to the CFD purchased by investors.